Poly(ADP-ribose) polymerase inhibitors in the treatment landscape of triple-negative breast cancer (TNBC).

Walaa Bayoumie El GazzarKhaled Anwer AlbakriHanan HasanAmira M BadrAmina A FaragOthman Mohammad Saleh

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)

PARPi are emerging treatment options for patients with gBRCA1/2 mutations. Determining patients that are most likely to benefit from PARPi and identifying the optimal treatment combinations with high efficacy and fewer side effects are currently ongoing.

Keyphrases

end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
prognostic factors
combination therapy
single cell
patient reported outcomes